ÓÉÑÏÖØ¼±ÐÔºôÎü×ÛºÏÕ÷¹Ú×´²¡¶¾2£¨SARS-CoV-2£©ÒýÆðµÄ2019¹Ú×´²¡¶¾¼²²¡´óÊ¢ÐУ¨COVID-19£©ÒýÆðÁËÈ«Çò¹Ø×¢¡£¡£¡£¡£¡£Ëæ×ÅÒßÇéµÄÉìÕÅ£¬£¬£¬£¬£¬£¬£¬ÕýÍþв×ÅÈ«Çò¹«¹²ÎÀÉú¡£¡£¡£¡£¡£¾ÝÌìÏÂÎÀÉú×éÖ¯6ÔÂ6ÈÕÐû²¼µÄ×îÐÂÊý¾ÝÏÔʾ£¬£¬£¬£¬£¬£¬£¬×èÖ¹±±¾©Ê±¼ä6ÈÕ16ʱ£¬£¬£¬£¬£¬£¬£¬È«Çò¹æÄ£ÄÚйڷÎÑ×È·ÕﲡÀý´ï6663304Àý£»£»£»£»£»éæÃü²¡ÀýµÖ´ï392802Àý¡£¡£¡£¡£¡£ÏÖÔÚΪֹ£¬£¬£¬£¬£¬£¬£¬»¹Ã»ÓÐÖÎÁÆCOVID-19µÄÓÐÓÃÒ©Î£¬£¬£¬£¬£¬£¬¿ª·¢ÒßÃçÒÔÔ¤·ÀºÍ¿ØÖÆCOVID-19ÆÈÔÚü½Þ¡£¡£¡£¡£¡£
![]()
2020Äê6ÔÂ6ÈÕ£¬£¬£¬£¬£¬£¬£¬ÖйúÉúÎï±±¾©ÉúÎïÖÆÆ·Ñо¿Ëù£¬£¬£¬£¬£¬£¬£¬Öйú¼²²¡Ô¤·À¿ØÖÆÖÐÐÄ¡¢Öйúҽѧ¿ÆÑ§ÔºµÈ¶àµ¥Î»ÏàÖú£¬£¬£¬£¬£¬£¬£¬ÕÅÔÆÌΡ¢¸ß¸£¡¢ÇØ´¨¡¢ÐìÃ硢̷ÎĽܡ¢Â¦ÖÇÓ¡¢À¹ó¡¢Îä¹ðÕäµÈÅäºÏÔÚ¡¶CELL¡·ÔÚÏß½ÒÏþÌâΪ¡°Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬£¬£¬ÏòÈ«ÇòÏÈÈÝйÚÒßÃçÑз¢Ï£Íû¡£¡£¡£¡£¡£
йÚÒßÃçÔÚ¶¯ÎïÄ£×ÓÖÐÄÜÓÕµ¼³ö
¸ßˮƽµÄÖкͿ¹ÌåµÎ¶È
¸ÃÑо¿±¨¸æÁËÃð»îµÄSARS-CoV-2ÒßÃçºòÑ¡ÎBBIBP-CorV£©µÄÖÐÊÔ¹æÄ££¬£¬£¬£¬£¬£¬£¬¸ÃÒßÃçÔÚСÊ󣬣¬£¬£¬£¬£¬£¬´óÊ󣬣¬£¬£¬£¬£¬£¬ëàÊ󣬣¬£¬£¬£¬£¬£¬ÍúͷÇÈËÀàÁ鳤ÀදÎʳзºïºÍºãºÓºï£©ÖÐÓÕµ¼¸ßˮƽµÄÖкͿ¹ÌåµÎ¶È£¬£¬£¬£¬£¬£¬£¬ÌṩÕë¶ÔSARS-CoV-2µÄ±£»£»£»£»£»¤¡£¡£¡£¡£¡£
ÖкͿ¹ÌåÊÇʲô£¿£¿£¿£¿£¿£¿£¿£¿
ÖкͿ¹ÌåÊǵ±²¡Ô΢ÉúÎïÇÖÈë»úÌåʱ»á±¬·¢µÄÏìÓ¦µÄ¿¹Ìå¡£¡£¡£¡£¡£µ±²¡¶¾ÇÖÈëÈËÌåÖ®ºó£¬£¬£¬£¬£¬£¬£¬ÃâÒßϸ°û°ÑÖкÍÂѰ×ÉøÍ¸µ½ÑªÒºÀ£¬£¬£¬£¬£¬£¬ºóÕßÓëѪҺÀïµÄ²¡¶¾¿ÅÁ£ÍŽᣬ£¬£¬£¬£¬£¬£¬×èÖ¹²¡¶¾Ñ¬È¾Ï¸°û£¬£¬£¬£¬£¬£¬£¬É¨³ý²¡¶¾£¬£¬£¬£¬£¬£¬£¬ÕâÑù¾Í°Ñ²¡¶¾¡°Öк͡±µôÁË¡£¡£¡£¡£¡£
¹¥¶¾ÊµÑéÏÔʾ£º
ÒßÃçÄÜÆðµ½ÓÐÓñ£»£»£»£»£»¤
ʹÓÃ2¦Ìg/Ö§µÄBBIBP-CorV¾ÙÐеÄÁ½¼Á´ÎÃâÒßΪºãºÓºïÌṩÁËÕë¶ÔSARS-CoV-2Æø¹ÜÄÚ¹¥»÷µÄ¸ßЧ±£»£»£»£»£»¤¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéÊÇʲô£¿£¿£¿£¿£¿£¿£¿£¿
ÒßÃçÃâÒߺ󣬣¬£¬£¬£¬£¬£¬µ¥µ¥±¬·¢¿¹Ì廹²»·ó¡£¡£¡£¡£¡£ÐèҪͨ¹ý¹¥¶¾ÊÔÑéÀ´ÑéÖ¤±¬·¢µÄ¿¹ÌåÄÜ·ñÕæÕý±£»£»£»£»£»¤»úÌåÃâÊÜѬȾ¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéÒ²³ÆÎª±£»£»£»£»£»¤ÐÔÊÔÑ飬£¬£¬£¬£¬£¬£¬¾ÍÊÇÏÈÓÃÒßÃç¶Ô»úÌå¾ÙÐÐ×¢ÉäÃâÒߣ¬£¬£¬£¬£¬£¬£¬´ý»úÌ屬·¢ÌØÒìÐÔ¿¹Ìåºó£¬£¬£¬£¬£¬£¬£¬ÓþßÓж¾Á¦µÄ²¡Ô΢ÉúÎï¶Ô»úÌå¾ÙÐÐѬȾ¹¥»÷£¬£¬£¬£¬£¬£¬£¬Í¨¹ýѬȾµÄЧ¹ûÀ´ÆÀ¼ÛÒßÃç¶Ô»úÌå¶Ô¿¹²¡Ô΢ÉúÎïµÄ±£»£»£»£»£»¤Ð§¹û¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéµÄЧ¹ûÊÇ×îÄÜ·´Ó¦ÒßÃçÓÐÓÃÐÔµÄÒªº¦Êý¾Ý¡£¡£¡£¡£¡£ËùÓеÄÐÂÒßÃç¶¼±ØÐè¾Óɱ£»£»£»£»£»¤ÐÔ¹¥¶¾ÊÔÑéÀ´Ö¤ÊµÒßÃçµÄÓÐÓÃÐÔ¡£¡£¡£¡£¡£
![]()
ÎÄÕÂ×ÊÁÏͼ£¨Í¼Ô´×ÔCell £©
δÊӲ쵽ADEÕ÷Ïó
¶ÔºãºÓºïʹÓÃ2¦Ìg/Ö§µÄBBIBP-CorV¾ÙÐÐÁ½¼Á´ÎÃâÒߣ¬£¬£¬£¬£¬£¬£¬Ã»Óмì²âµ½¿¹ÌåÒÀÀµÐÔÔöǿѬȾ¡£¡£¡£¡£¡£
ÕâЩЧ¹û¾ùÓÐÁ¦Ö§³ÖÔÚÈËÌåÁÙ´²ÊÔÑéÖнøÒ»²½ÆÀ¹ÀBBIBP-CorV¡£¡£¡£¡£¡£
ʲôÊÇADE£¿£¿£¿£¿£¿£¿£¿£¿
ADEµÄÈ«³ÆÊÇ£ºAntibody-dependent Enhancement£¬£¬£¬£¬£¬£¬£¬¼´¿¹ÌåÒÀÀµÔöÇ¿×÷Ó㬣¬£¬£¬£¬£¬£¬Ö¸µÄÊÇÔ±¾Í¨¹ý×¢ÉäÒßÃçºóÓ¦µ±ÐγɶԿ¹²¡¶¾µÄ¿¹Ì壬£¬£¬£¬£¬£¬£¬ÒòijЩԵ¹ÊÔÓÉ·´¶øÊ¹²¡¶¾µÄѬȾÐÔÔöÇ¿£¬£¬£¬£¬£¬£¬£¬Îª²¡¶¾¡°Öú¹¥¡±¡£¡£¡£¡£¡£
Ñо¿Ö°Ô±×îÔçÔڵǸïÈÈ»¼ÕßÖÐÊӲ쵽ADEЧӦÕâÒ»Õ÷Ïó
±±¾©ÉúÎïйÚÒßÃçÉú²ú³µ¼äÒѽ¨³É
Äê²úÁ¿´ï1ÒÚ¼Á
йÚÃð»îÒßÃçÉú²ú³µ¼äµÄ½¨³ÉÌî²¹Á˺£ÄÚÖØ´óз¢Í»·¢Ñ¬È¾²¡·À¿ØÔÚÒßÃçÁìÓòµÄÉúÎïÇå¾²¿Õȱ£¬£¬£¬£¬£¬£¬£¬¶ÔйڷÎÑ×ÒßÇéµÄÒ©Æ·ºÍÒßÃçÑб¬·¢²úÒâÒåÖØ´ó¡£¡£¡£¡£¡£×÷ΪÏÖÔÚÈ«Çò×î´óµÄйÚÃð»îÒßÃçÉú²ú³µ¼ä£¬£¬£¬£¬£¬£¬£¬ÔÚ¹ú¼ÒÓйز¿Î¯ºÍ±±¾©ÊÐÕþ¸®µÄ¶¦Á¦´ó¾ÙÖ§³ÖÏ£¬£¬£¬£¬£¬£¬£¬±±¾©ÉúÎïÖÆÆ·Ñо¿Ëù½öÓÃ2¸öÔµÄʱ¼ä£¬£¬£¬£¬£¬£¬£¬ÓÚ4ÔÂ15ÈÕ¾ÍÍê³ÉÁ˳µ¼äµÄ½¨É裬£¬£¬£¬£¬£¬£¬¾Óɹú¼Ò¼¶ÉúÎïÇ徲ר¼ÒµÄÏÖ³¡ÆðÔ´ÆÀ¹À£¬£¬£¬£¬£¬£¬£¬½¨Éè±ê×¼ºÍÖÊÁ¿Ë®Æ½Öª×ãÉúÎïÇå¾²·À»¤ÒªÇ󣬣¬£¬£¬£¬£¬£¬´´Á¢ÁËйÚÃð»îÒßÃç³µ¼ä½¨ÉèµÄ¡°»ðÉñɽ¡±ËÙÂÊ¡£¡£¡£¡£¡£³µ¼äÅú´Î²úÁ¿Áè¼Ý300Íò¼Á£¬£¬£¬£¬£¬£¬£¬Á¿²úºóÄê²úÄÜ´ï1-1.2ÒÚ¼Á¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬£¬Î人ÉúÎïÖÆÆ·Ñо¿ËùйÚÃð»îÒßÃç³µ¼ä½¨ÉèÔ¤¼Æ½«ÓÚ6ÔÂβ»ò7Ô³õÍê³É¡£¡£¡£¡£¡£½ìʱÖйúÉúÎïÁ½¸öÑо¿Ëù¼ÓÆðÀ´£¬£¬£¬£¬£¬£¬£¬Äê²úÄܿɴï2ÒÚ¼ÁÒÔÉÏ£¬£¬£¬£¬£¬£¬£¬°ü¹ÜйÚÃð»îÒßÃçµÄ¿É¼°ÐÔ¡£¡£¡£¡£¡£
ÖйúÉúÎォÐÒ²»ÈèÃü£¡
ÔöÇ¿¿ÆÑС¢Éú²úºÍÖÊÁ¿ÖÎÀí
Î§ÈÆ¿ÉÕï¡¢¿ÉÖΡ¢¿É·ÀµÄÄ¿µÄ£¬£¬£¬£¬£¬£¬£¬
ÑÏ¿áÆ¾Ö¤Ïà¹ØÖ´ÂÉÀýÔò£¬£¬£¬£¬£¬£¬£¬
¼ÌÐøÔöÇ¿¿Æ¼¼¹¥¹Ø£¬£¬£¬£¬£¬£¬£¬ÎªÊµÏÖйÚÃð»îÒßÃçµÄ
Çå¾²ÐÔ¡¢ÓÐÓÃÐÔ¡¢¿É¼°ÐÔ£¬£¬£¬£¬£¬£¬£¬
°ü¹ÜÈËÃñÉúÃü¿µ½¡Ð¢Ë³×î´óµÄʵÁ¦¡£¡£¡£¡£¡£

¾©¹«Íø°²±¸ 11040102700104ºÅ
¾©ICP±¸£º14023670ºÅ-1
ÓÉÑÏÖØ¼±ÐÔºôÎü×ÛºÏÕ÷¹Ú×´²¡¶¾2£¨SARS-CoV-2£©ÒýÆðµÄ2019¹Ú×´²¡¶¾¼²²¡´óÊ¢ÐУ¨COVID-19£©ÒýÆðÁËÈ«Çò¹Ø×¢¡£¡£¡£¡£¡£Ëæ×ÅÒßÇéµÄÉìÕÅ£¬£¬£¬£¬£¬£¬£¬ÕýÍþв×ÅÈ«Çò¹«¹²ÎÀÉú¡£¡£¡£¡£¡£¾ÝÌìÏÂÎÀÉú×éÖ¯6ÔÂ6ÈÕÐû²¼µÄ×îÐÂÊý¾ÝÏÔʾ£¬£¬£¬£¬£¬£¬£¬×èÖ¹±±¾©Ê±¼ä6ÈÕ16ʱ£¬£¬£¬£¬£¬£¬£¬È«Çò¹æÄ£ÄÚйڷÎÑ×È·ÕﲡÀý´ï6663304Àý£»£»£»£»£»éæÃü²¡ÀýµÖ´ï392802Àý¡£¡£¡£¡£¡£ÏÖÔÚΪֹ£¬£¬£¬£¬£¬£¬£¬»¹Ã»ÓÐÖÎÁÆCOVID-19µÄÓÐÓÃÒ©Î£¬£¬£¬£¬£¬£¬¿ª·¢ÒßÃçÒÔÔ¤·ÀºÍ¿ØÖÆCOVID-19ÆÈÔÚü½Þ¡£¡£¡£¡£¡£
![]()
2020Äê6ÔÂ6ÈÕ£¬£¬£¬£¬£¬£¬£¬ÖйúÉúÎï±±¾©ÉúÎïÖÆÆ·Ñо¿Ëù£¬£¬£¬£¬£¬£¬£¬Öйú¼²²¡Ô¤·À¿ØÖÆÖÐÐÄ¡¢Öйúҽѧ¿ÆÑ§ÔºµÈ¶àµ¥Î»ÏàÖú£¬£¬£¬£¬£¬£¬£¬ÕÅÔÆÌΡ¢¸ß¸£¡¢ÇØ´¨¡¢ÐìÃ硢̷ÎĽܡ¢Â¦ÖÇÓ¡¢À¹ó¡¢Îä¹ðÕäµÈÅäºÏÔÚ¡¶CELL¡·ÔÚÏß½ÒÏþÌâΪ¡°Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬£¬£¬ÏòÈ«ÇòÏÈÈÝйÚÒßÃçÑз¢Ï£Íû¡£¡£¡£¡£¡£
йÚÒßÃçÔÚ¶¯ÎïÄ£×ÓÖÐÄÜÓÕµ¼³ö
¸ßˮƽµÄÖкͿ¹ÌåµÎ¶È
¸ÃÑо¿±¨¸æÁËÃð»îµÄSARS-CoV-2ÒßÃçºòÑ¡ÎBBIBP-CorV£©µÄÖÐÊÔ¹æÄ££¬£¬£¬£¬£¬£¬£¬¸ÃÒßÃçÔÚСÊ󣬣¬£¬£¬£¬£¬£¬´óÊ󣬣¬£¬£¬£¬£¬£¬ëàÊ󣬣¬£¬£¬£¬£¬£¬ÍúͷÇÈËÀàÁ鳤ÀදÎʳзºïºÍºãºÓºï£©ÖÐÓÕµ¼¸ßˮƽµÄÖкͿ¹ÌåµÎ¶È£¬£¬£¬£¬£¬£¬£¬ÌṩÕë¶ÔSARS-CoV-2µÄ±£»£»£»£»£»¤¡£¡£¡£¡£¡£
ÖкͿ¹ÌåÊÇʲô£¿£¿£¿£¿£¿£¿£¿£¿
ÖкͿ¹ÌåÊǵ±²¡Ô΢ÉúÎïÇÖÈë»úÌåʱ»á±¬·¢µÄÏìÓ¦µÄ¿¹Ìå¡£¡£¡£¡£¡£µ±²¡¶¾ÇÖÈëÈËÌåÖ®ºó£¬£¬£¬£¬£¬£¬£¬ÃâÒßϸ°û°ÑÖкÍÂѰ×ÉøÍ¸µ½ÑªÒºÀ£¬£¬£¬£¬£¬£¬ºóÕßÓëѪҺÀïµÄ²¡¶¾¿ÅÁ£ÍŽᣬ£¬£¬£¬£¬£¬£¬×èÖ¹²¡¶¾Ñ¬È¾Ï¸°û£¬£¬£¬£¬£¬£¬£¬É¨³ý²¡¶¾£¬£¬£¬£¬£¬£¬£¬ÕâÑù¾Í°Ñ²¡¶¾¡°Öк͡±µôÁË¡£¡£¡£¡£¡£
¹¥¶¾ÊµÑéÏÔʾ£º
ÒßÃçÄÜÆðµ½ÓÐÓñ£»£»£»£»£»¤
ʹÓÃ2¦Ìg/Ö§µÄBBIBP-CorV¾ÙÐеÄÁ½¼Á´ÎÃâÒßΪºãºÓºïÌṩÁËÕë¶ÔSARS-CoV-2Æø¹ÜÄÚ¹¥»÷µÄ¸ßЧ±£»£»£»£»£»¤¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéÊÇʲô£¿£¿£¿£¿£¿£¿£¿£¿
ÒßÃçÃâÒߺ󣬣¬£¬£¬£¬£¬£¬µ¥µ¥±¬·¢¿¹Ì廹²»·ó¡£¡£¡£¡£¡£ÐèҪͨ¹ý¹¥¶¾ÊÔÑéÀ´ÑéÖ¤±¬·¢µÄ¿¹ÌåÄÜ·ñÕæÕý±£»£»£»£»£»¤»úÌåÃâÊÜѬȾ¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéÒ²³ÆÎª±£»£»£»£»£»¤ÐÔÊÔÑ飬£¬£¬£¬£¬£¬£¬¾ÍÊÇÏÈÓÃÒßÃç¶Ô»úÌå¾ÙÐÐ×¢ÉäÃâÒߣ¬£¬£¬£¬£¬£¬£¬´ý»úÌ屬·¢ÌØÒìÐÔ¿¹Ìåºó£¬£¬£¬£¬£¬£¬£¬ÓþßÓж¾Á¦µÄ²¡Ô΢ÉúÎï¶Ô»úÌå¾ÙÐÐѬȾ¹¥»÷£¬£¬£¬£¬£¬£¬£¬Í¨¹ýѬȾµÄЧ¹ûÀ´ÆÀ¼ÛÒßÃç¶Ô»úÌå¶Ô¿¹²¡Ô΢ÉúÎïµÄ±£»£»£»£»£»¤Ð§¹û¡£¡£¡£¡£¡£
¹¥¶¾ÊÔÑéµÄЧ¹ûÊÇ×îÄÜ·´Ó¦ÒßÃçÓÐÓÃÐÔµÄÒªº¦Êý¾Ý¡£¡£¡£¡£¡£ËùÓеÄÐÂÒßÃç¶¼±ØÐè¾Óɱ£»£»£»£»£»¤ÐÔ¹¥¶¾ÊÔÑéÀ´Ö¤ÊµÒßÃçµÄÓÐÓÃÐÔ¡£¡£¡£¡£¡£
![]()
ÎÄÕÂ×ÊÁÏͼ£¨Í¼Ô´×ÔCell £©
δÊӲ쵽ADEÕ÷Ïó
¶ÔºãºÓºïʹÓÃ2¦Ìg/Ö§µÄBBIBP-CorV¾ÙÐÐÁ½¼Á´ÎÃâÒߣ¬£¬£¬£¬£¬£¬£¬Ã»Óмì²âµ½¿¹ÌåÒÀÀµÐÔÔöǿѬȾ¡£¡£¡£¡£¡£
ÕâЩЧ¹û¾ùÓÐÁ¦Ö§³ÖÔÚÈËÌåÁÙ´²ÊÔÑéÖнøÒ»²½ÆÀ¹ÀBBIBP-CorV¡£¡£¡£¡£¡£
ʲôÊÇADE£¿£¿£¿£¿£¿£¿£¿£¿
ADEµÄÈ«³ÆÊÇ£ºAntibody-dependent Enhancement£¬£¬£¬£¬£¬£¬£¬¼´¿¹ÌåÒÀÀµÔöÇ¿×÷Ó㬣¬£¬£¬£¬£¬£¬Ö¸µÄÊÇÔ±¾Í¨¹ý×¢ÉäÒßÃçºóÓ¦µ±ÐγɶԿ¹²¡¶¾µÄ¿¹Ì壬£¬£¬£¬£¬£¬£¬ÒòijЩԵ¹ÊÔÓÉ·´¶øÊ¹²¡¶¾µÄѬȾÐÔÔöÇ¿£¬£¬£¬£¬£¬£¬£¬Îª²¡¶¾¡°Öú¹¥¡±¡£¡£¡£¡£¡£
Ñо¿Ö°Ô±×îÔçÔڵǸïÈÈ»¼ÕßÖÐÊӲ쵽ADEЧӦÕâÒ»Õ÷Ïó
±±¾©ÉúÎïйÚÒßÃçÉú²ú³µ¼äÒѽ¨³É
Äê²úÁ¿´ï1ÒÚ¼Á
йÚÃð»îÒßÃçÉú²ú³µ¼äµÄ½¨³ÉÌî²¹Á˺£ÄÚÖØ´óз¢Í»·¢Ñ¬È¾²¡·À¿ØÔÚÒßÃçÁìÓòµÄÉúÎïÇå¾²¿Õȱ£¬£¬£¬£¬£¬£¬£¬¶ÔйڷÎÑ×ÒßÇéµÄÒ©Æ·ºÍÒßÃçÑб¬·¢²úÒâÒåÖØ´ó¡£¡£¡£¡£¡£×÷ΪÏÖÔÚÈ«Çò×î´óµÄйÚÃð»îÒßÃçÉú²ú³µ¼ä£¬£¬£¬£¬£¬£¬£¬ÔÚ¹ú¼ÒÓйز¿Î¯ºÍ±±¾©ÊÐÕþ¸®µÄ¶¦Á¦´ó¾ÙÖ§³ÖÏ£¬£¬£¬£¬£¬£¬£¬±±¾©ÉúÎïÖÆÆ·Ñо¿Ëù½öÓÃ2¸öÔµÄʱ¼ä£¬£¬£¬£¬£¬£¬£¬ÓÚ4ÔÂ15ÈÕ¾ÍÍê³ÉÁ˳µ¼äµÄ½¨É裬£¬£¬£¬£¬£¬£¬¾Óɹú¼Ò¼¶ÉúÎïÇ徲ר¼ÒµÄÏÖ³¡ÆðÔ´ÆÀ¹À£¬£¬£¬£¬£¬£¬£¬½¨Éè±ê×¼ºÍÖÊÁ¿Ë®Æ½Öª×ãÉúÎïÇå¾²·À»¤ÒªÇ󣬣¬£¬£¬£¬£¬£¬´´Á¢ÁËйÚÃð»îÒßÃç³µ¼ä½¨ÉèµÄ¡°»ðÉñɽ¡±ËÙÂÊ¡£¡£¡£¡£¡£³µ¼äÅú´Î²úÁ¿Áè¼Ý300Íò¼Á£¬£¬£¬£¬£¬£¬£¬Á¿²úºóÄê²úÄÜ´ï1-1.2ÒÚ¼Á¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬£¬Î人ÉúÎïÖÆÆ·Ñо¿ËùйÚÃð»îÒßÃç³µ¼ä½¨ÉèÔ¤¼Æ½«ÓÚ6ÔÂβ»ò7Ô³õÍê³É¡£¡£¡£¡£¡£½ìʱÖйúÉúÎïÁ½¸öÑо¿Ëù¼ÓÆðÀ´£¬£¬£¬£¬£¬£¬£¬Äê²úÄܿɴï2ÒÚ¼ÁÒÔÉÏ£¬£¬£¬£¬£¬£¬£¬°ü¹ÜйÚÃð»îÒßÃçµÄ¿É¼°ÐÔ¡£¡£¡£¡£¡£
ÖйúÉúÎォÐÒ²»ÈèÃü£¡
ÔöÇ¿¿ÆÑС¢Éú²úºÍÖÊÁ¿ÖÎÀí
Î§ÈÆ¿ÉÕï¡¢¿ÉÖΡ¢¿É·ÀµÄÄ¿µÄ£¬£¬£¬£¬£¬£¬£¬
ÑÏ¿áÆ¾Ö¤Ïà¹ØÖ´ÂÉÀýÔò£¬£¬£¬£¬£¬£¬£¬
¼ÌÐøÔöÇ¿¿Æ¼¼¹¥¹Ø£¬£¬£¬£¬£¬£¬£¬ÎªÊµÏÖйÚÃð»îÒßÃçµÄ
Çå¾²ÐÔ¡¢ÓÐÓÃÐÔ¡¢¿É¼°ÐÔ£¬£¬£¬£¬£¬£¬£¬
°ü¹ÜÈËÃñÉúÃü¿µ½¡Ð¢Ë³×î´óµÄʵÁ¦¡£¡£¡£¡£¡£
¹«°²±¸°¸ºÅ£º11040102700104ºÅ